Immune Checkpoint Inhibitors Have Transformed Cancer Treatment – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Anniek Strijdhorst et al, adding:
“Immune checkpoint inhibitors and thrombosis: are antiphospholipid antibodies to blame?
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but they are associated with an increased risk of both venous and arterial thromboembolism. The mechanisms behind this remain poorly understood.
One hypothesis: ICI therapy might trigger the development of antiphospholipid antibodies, leading to hypercoagulability.
A new prospective study from the ITHACA cohort, published in RPTH Journal, puts this hypothesis to the test.
- Key findings from 40 patients assessed before and after 3 months of ICI therapy:
- No significant development of antiphospholipid antibody positivity after 3 months (8% at baseline vs 5% at 3 months)
- No patients developed a positive lupus anticoagulant
- Thrombin generation remained unchanged
- Only 1 patient developed VTE during follow-up
The short-term thrombotic risk associated with ICI therapy does not appear to be mediated by antiphospholipid antibodies, pointing researchers toward other mechanisms that still need to be uncovered.”
Title: Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study
Authors: Anniek Strijdhorst, Dorien M. Salet, Jente M. Schoenaker, Vossa van der Vegte, Tom T.P. Seijkens, Hanneke W.M. van Laarhoven, Rolf T. Urbanus, Nick van Es

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026